BACKGROUND: We retrospectively analyzed the clinical characteristics and outcomes of various racial and ethnic groups who underwent radiotherapy alone for localized or locally advanced prostate cancer. METHODS: From April 1987 to January 1998, 964 patients underwent full-dose, external-beam radiotherapy alone for localized or locally advanced prostate cancer and were included in the study. The patients' medical records were reviewed for pertinent information. RESULTS: Of the 964 patients, 810 were non-Hispanic white, 86 were African-American, 54 were Hispanic, and 14 were Asian. The most significant difference between groups was in the proportion of patients who presented with initial PSA levels > 20 ng/ml. More than 20% of men in all minority groups presented with a serum PSA > 20 ng/ml, compared to only 11% of whites (p = 0.0012). Similarly, 14% of minorities presented with Gleason scores > or = 8 compared to only 11% of whites (p = 0.0265). Hispanic and Asian patients exhibited a higher incidence of Gleason score > or = 8 prostate cancer. When comparing the time intervals of 1995-1998 vs. 1987-1994, the number of men presenting for EBRT with PSA levels < 10 ng/ml increased to 74% from 57% for Caucasians (p < 0,001), 71% from 40% for African Americans (p = 0.012), 67% from 49% for Hispanics (p = 0.1 18), and no change (50%) for Asians. CONCLUSIONS: The number of African-American patients presenting with favorable characteristics (PSA < 10 ng/ml) is increasing. These findings suggest that the message of screening and early detection may be reaching the African-American community. Continued diligence in screening and early detection may improve prostate cancer outcome for other minority populations.
BACKGROUND: We retrospectively analyzed the clinical characteristics and outcomes of various racial and ethnic groups who underwent radiotherapy alone for localized or locally advanced prostate cancer. METHODS: From April 1987 to January 1998, 964 patients underwent full-dose, external-beam radiotherapy alone for localized or locally advanced prostate cancer and were included in the study. The patients' medical records were reviewed for pertinent information. RESULTS: Of the 964 patients, 810 were non-Hispanic white, 86 were African-American, 54 were Hispanic, and 14 were Asian. The most significant difference between groups was in the proportion of patients who presented with initial PSA levels > 20 ng/ml. More than 20% of men in all minority groups presented with a serum PSA > 20 ng/ml, compared to only 11% of whites (p = 0.0012). Similarly, 14% of minorities presented with Gleason scores > or = 8 compared to only 11% of whites (p = 0.0265). Hispanic and Asian patients exhibited a higher incidence of Gleason score > or = 8 prostate cancer. When comparing the time intervals of 1995-1998 vs. 1987-1994, the number of men presenting for EBRT with PSA levels < 10 ng/ml increased to 74% from 57% for Caucasians (p < 0,001), 71% from 40% for African Americans (p = 0.012), 67% from 49% for Hispanics (p = 0.1 18), and no change (50%) for Asians. CONCLUSIONS: The number of African-American patients presenting with favorable characteristics (PSA < 10 ng/ml) is increasing. These findings suggest that the message of screening and early detection may be reaching the African-American community. Continued diligence in screening and early detection may improve prostate cancer outcome for other minority populations.
Authors: A Pollack; G K Zagars; L G Smith; J J Lee; A C von Eschenbach; J A Antolak; G Starkschall; I Rosen Journal: J Clin Oncol Date: 2000-12-01 Impact factor: 44.544
Authors: J P Austin; H Aziz; L Potters; W Thelmo; P Chen; K Choi; M Brandys; R J Macchia; M Rotman Journal: Am J Clin Oncol Date: 1990-12 Impact factor: 2.339
Authors: R M Hoffman; F D Gilliland; J W Eley; L C Harlan; R A Stephenson; J L Stanford; P C Albertson; A S Hamilton; W C Hunt; A L Potosky Journal: J Natl Cancer Inst Date: 2001-03-07 Impact factor: 13.506
Authors: Paul A Godley; Anna P Schenck; M Ahinee Amamoo; Victor J Schoenbach; Sharon Peacock; Michelle Manning; Michael Symons; James A Talcott Journal: J Natl Cancer Inst Date: 2003-11-19 Impact factor: 13.506
Authors: Matthew H Hayn; Heather Orom; Vickie L Shavers; Martin G Sanda; Mark Glasgow; James L Mohler; Willie Underwood Journal: Cancer Date: 2011-03-31 Impact factor: 6.860